Clinical Trials
210 trialsA Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
BeOne Medicines
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
Integro Theranostics
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Abdera Therapeutics Inc.
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Pfizer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
DeuterOncology
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics, Inc.
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Pfizer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
GUARDIAN-101
Clasp Therapeutics, Inc.
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Xemed LLC
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen Inc.
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
ACT
AgonOx, Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis